DocDollars

Boehringer Ingelheim Pharma GMBH & Co.KG

Germany · Reporting entity ID 100000010823

Total reported 2019–2025
$61.1M
#146 of 2,960 reporting companies — 0.1% of all reported industry payments
$566K in general payments across 320 records, plus $60.5M in research funding across 13,991 records.

How it breaks down

General payments $565,806
Research funding $60,535,723

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Boehringer Ingelheim Pharma GMBH & Co.KG reported $61.1M to US doctors and teaching hospitals from 2019 to 2025, ranking #146 of 2,960 reporting companies. 99% of that was research funding and 1% general payments such as consulting, speaking, food and travel. 320 general payment records and 13,991 research records were filed.

Common questions about Boehringer Ingelheim Pharma GMBH & Co.KG

How much has Boehringer Ingelheim Pharma GMBH & Co.KG paid US doctors?

Boehringer Ingelheim Pharma GMBH & Co.KG reported $61,101,529 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $565,806 in general payments, $60,535,723 in research funding.

How does Boehringer Ingelheim Pharma GMBH & Co.KG rank among drug and device companies?

It ranks #146 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Boehringer Ingelheim Pharma GMBH & Co.KG mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.